GHO Capital Acquires Ardena, a European Early‑Stage CDMO
January 9, 2020
GHO Capital Partners LLP has acquired Ardena, a Belgium‑headquartered contract development and manufacturing organisation (CDMO) focused on early‑phase drug development, from Mentha Capital and existing management. GHO will partner with Ardena's management to accelerate international growth, broaden the company’s service offering and build a fully integrated early‑stage CDMO platform through organic and inorganic expansion.
- Buyers
- GHO Capital Partners LLP
- Targets
- Ardena
- Sellers
- Mentha Capital, Existing management
- Industry
- Pharmaceuticals
- Location
- East Flanders, Belgium
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Ardena Acquires Catalent's Somerset, New Jersey Drug Product Facility
October 14, 2024
Pharmaceuticals
Ardena, a GHO Capital-backed CDMO, has signed a definitive agreement to acquire Catalent's FDA-approved drug product manufacturing facility in Somerset, New Jersey. The acquisition — expected to close in early 2025 subject to approvals — expands Ardena's US footprint and downstream capabilities in oral solid dosage manufacturing and bioanalytical services.
-
Astorg Acquires Pharmaceutical CDMO CordenPharma from ICIG
May 2, 2022
Pharmaceuticals
Astorg has signed a binding agreement to acquire CordenPharma, a global contract development and manufacturing organization (CDMO) focused on APIs, excipients and drug products, from International Chemical Investors Group (ICIG). CordenPharma employs over 2,600 people across 11 manufacturing sites and an R&D laboratory in Europe and the US; the founders will reinvest alongside Astorg. The transaction is subject to customary regulatory approvals and terms were not disclosed.
-
GHO Capital Invests in RoslinCT
January 11, 2022
Biotechnology
GHO Capital Partners LLP has made a growth equity investment in RoslinCT, a UK-based contract development and manufacturing organisation (CDMO) focused on advanced cell therapies. The capital will support scaling of RoslinCT’s cGMP manufacturing capacity, international customer acquisition and product diversification to drive commercial-scale cell therapy manufacturing.
-
Adare Pharma Solutions Acquires Frontida BioPharm
December 1, 2021
Pharmaceuticals
Adare Pharma Solutions, a PE-backed contract development and manufacturing organization (CDMO), has acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The deal expands Adare’s capabilities—including high-potency compound handling and packaging services—and increases its manufacturing footprint; Adare is backed by Thomas H. Lee Partners and Frazier Healthcare Partners.
-
Ardena (GHO Capital Portfolio) Acquires Idifarma from Suanfarma and Sodena
September 2, 2021
Healthcare Services
Ardena, a GHO Capital-backed specialist pharmaceutical CDMO, has acquired Idifarma from Suanfarma and Sodena. The deal expands Ardena's European footprint and adds Idifarma's spray drying technology and high-potency drug capabilities at its Pamplona site, supporting Ardena's integrated end-to-end CDMO strategy.
-
GHO Capital Leads Consortium to Acquire Majority Stake in Envision Pharma Group from Ardian
November 5, 2020
Healthcare Services
GHO Capital Partners, leading a consortium that includes Mubadala Investment Company, HarbourVest Partners and Northwestern Mutual, together with Envision management and employees, has acquired a majority stake in Envision Pharma Group as Ardian exits its investment. The transaction will support Envision's continued growth, wider rollout of its iEnvision medical affairs platform and strategic acquisitions to expand its medical affairs, communications and technology capabilities.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.